Robinson Vidva

Robinson Vidva

Auto-generated profile, based on publicly available information

Robinson Vidva

Center for Neuroscience Research and Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, Washington, DC, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2014 in Scientific Reports
Verified
Journal Article
Open access
DBDerek S. Borgwardt
Derek S. Borgwardt
AMAaron D. Martin
Aaron D. Martin
JHJonathan R. Van Hemert
Jonathan R. Van Hemert
JYJianyi Yang
Jianyi Yang
CFCarol Fischer
Carol Fischer
KBKim Alan Brogden
Kim Alan Brogden
Histatins are human salivary gland peptides with anti-microbial and anti-inflammatory activities. In this study, we hypothesized that histatin 5 binds to Porphyromonas gingivalis hemagglutinin B (HagB) and attenuates HagB-induced chemokine responses in human myeloid dendritic cells. Histatin 5 bound to immobilized HagB in a surface plasmon resonance (SPR) spectroscopy-based biosensor system. SPR spectroscopy kinetic and equilibrium analyses, protein microarray studies, and I-TASSER structural modeling studies all demonstrated two histatin 5 binding sites on HagB. One site had a stronger affinity with a K-D1 of 1.9 mu M and one site had a weaker affinity with a K-D2 of 60.0 mu M. Binding has biological implications and predictive modeling studies and exposure of dendritic cells both demonstrated that 20.0 mu M histatin 5 attenuated (p < 0.05) 0.02 mu M HagB-induced CCL3/MIP-1 alpha, CCL4/MIP-1 beta, and TNF alpha responses. Thus histatin 5 is capable of attenuating chemokine responses, which may help control oral inflammation.

6 February 2013 in Scientific Reports
Verified
Journal Article
Open access
LHLauren E. Harvey
Lauren E. Harvey
KKKarl G. Kohlgraf
Karl G. Kohlgraf
LMLeslie A. Mehalick
Leslie A. Mehalick
MRMonica Raina
Monica Raina
ERErica N. Recker
Erica N. Recker
KBKim Alan Brogden
Kim Alan Brogden
Human β defensin DEFB103 acts as both a stimulant and an attenuator of chemokine and cytokine responses: a dichotomy that is not entirely understood. Our predicted results using an in silico simulation model of dendritic cells and our observed results in human myeloid dendritic cells, show that DEFB103 significantly (p < 0.05) enhanced 6 responses, attenuated 7 responses, and both enhanced/attenuated the CXCL1 and TNF responses to Porphyromonas gingivalis hemagglutinin B (HagB). In murine JAWSII dendritic cells, DEFB103 significantly attenuated, yet rarely enhanced, the Cxcl2, Il6, and Csf3 responses to HagB; and in C57/BL6 mice, DEFB103 significantly enhanced, yet rarely attenuated, the Cxcl1, Csf1, and Csf3 responses. Thus, DEFB103 influences pro-inflammatory activities with the concentration of DEFB103 and order of timing of DEFB103 exposure to dendritic cells, with respect to microbial antigen exposure to cells, being paramount in orchestrating the onset, magnitude, and composition of the chemokine and cytokine response.

1 February 2019 in Leukemia Research
Verified
Journal Article
Open access
LDLeylah M. Drusbosky
Leylah M. Drusbosky
RVRobinson Vidva
Robinson Vidva
SGSaji Gera
Saji Gera
ALAnjanasree V. Lakshminarayana
Anjanasree V. Lakshminarayana
VSVijayashree P. Shyamasundar
Vijayashree P. Shyamasundar
Christopher CogleChristopher Cogle
Christopher Cogle
Despite advances in understanding the molecular pathogenesis of acute myeloid leukaemia (AML), overall survival rates remain low. The ability to predict treatment response based on individual cancer genomics using computational modeling will aid in the development of novel therapeutics and personalize care. Here, we used a combination of genomics, computational biology modeling (CBM), ex vivo chemosensitivity assay, and clinical data from 100 randomly selected patients in the Beat AML project to characterize AML sensitivity to a bromodomain (BRD) and extra-terminal (BET) inhibitor. Computational biology modeling was used to generate patient-specific protein network maps of activated and inactivated protein pathways translated from each genomic profile. Digital drug simulations of a BET inhibitor (JQ1) were conducted by quantitatively measuring drug effect using a composite AML disease inhibition score. 93% of predicted disease inhibition scores matched the associated ex vivo IC50 value. Sensitivity and specificity of CBM predictions were 97.67%, and 64.29%, respectively. Genomic predictors of response were identified. Patient samples harbouring chromosomal aberrations del(7q) or -7, +8, or del(5q) and somatic mutations causing ERK pathway dysregulation, responded to JQ1 in both in silico and ex vivo assays. This study shows how a combination of genomics, computational modeling and chemosensitivity testing can identify network signatures associating with treatment response and can inform priority populations for future clinical trials of BET inhibitors.

26 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CFCarol Fischer
Carol Fischer
ABAmber M. Bates
Amber M. Bates
ELEmily A. Lanzel
Emily A. Lanzel
JGJanet M. Guthmiller
Janet M. Guthmiller
GJGeorgia K. Johnson
Georgia K. Johnson
KBKim Alan Brogden
Kim Alan Brogden
Individual computational models of single myeloid, lymphoid, epithelial, and cancer cells were created and combined into multi-cell computational models and used to predict the collective chemokine, cytokine, and cellular biomarker profiles often seen in inflamed or cancerous tissues. Predicted chemokine and cytokine output profiles from multi-cell computational models of gingival epithelial keratinocytes (GE KER), dendritic cells (DC), and helper T lymphocytes (HTL) exposed to lipopolysaccharide (LPS) or synthetic triacylated lipopeptide (Pam3CSK4) as well as multi-cell computational models of multiple myeloma (MM) and DC were validated using the observed chemokine and cytokine responses from the same cell type combinations grown in laboratory multi-cell cultures with accuracy. Predicted and observed chemokine and cytokine responses of GE KER + DC + HTL exposed to LPS and Pam3CSK4 matched 75% (15/20, p = 0.02069) and 80% (16/20, P = 0.005909), respectively. Multi-cell computational models became ‘personalized’ when cell line-specific genomic data were included into simulations, again validated with the same cell lines grown in laboratory multi-cell cultures. Here, predicted and observed chemokine and cytokine responses of MM cells lines MM.1S and U266B1 matched 75% (3/4) and MM.1S and U266B1 inhibition of DC marker expression in co-culture matched 100% (6/6). Multi-cell computational models have the potential to identify approaches altering the predicted disease-associated output profiles, particularly as high throughput screening tools for anti-inflammatory or immuno-oncology treatments of inflamed multi-cellular tissues and the tumor microenvironment.

29 October 2026 in Science
Verified
Journal Article
Closed access
GSGeorgios Sanidas
Georgios Sanidas
GSGabriele Simonti
Gabriele Simonti
JGJavid Ghaemmaghami
Javid Ghaemmaghami
KWKyla Woyshner
Kyla Woyshner
APAntonis Polyviou
Antonis Polyviou
PKPanagiotis Kratimenos
Panagiotis Kratimenos
Intrinsic programs shape brain maturation; however, which of these programs are perturbed by prematurity as well as the molecular pathways involved remain unknown. The human cerebellum serves as a paradigm of extrauterine development—its accelerated growth and circuit formation align with the third trimester, a period disrupted by preterm delivery. Using multimodal datasets encompassing in vivo neuroimaging and neurodevelopmental outcomes with postmortem spatial-transcriptomic and histopathological profiling, we show that prematurity diverts the cerebellar developmental trajectory. Cerebellar growth and functional outcomes scaled with gestational age, despite modifying perinatal exposures. Spatially resolved developmental programs underlying macroscopic trajectories were marked by incomplete granule cell maturation and impaired Purkinje cell structural refinement, which indicate lineage-specific developmental asynchrony. Thus, prematurity constitutes biologically displaced maturation, in which infants of equivalent postmenstrual age occupy divergent developmental states.

29 November 2018 in Blood
Verified
Journal Article
Closed access
JTJeffrey W. Tyner
Jeffrey W. Tyner
BDBrian J. Druker
Brian J. Druker
SKStephen E Kurtz
Stephen E Kurtz
CTCristina E. Tognon
Cristina E. Tognon
LDLeylah M. Drusbosky
Leylah M. Drusbosky
CCChristopher R. Cogle
Christopher R. Cogle
Background: In AML, leukemic transformation causes clonal expansion of immature cells through de-regulated cell division cycles. CDK4/CDK6 regulates neoplastic progression, which might represent an effective strategy for treating AML. But current clinical data shows either limited efficacy or elusive results. Bromodomain and extra-terminal (BET) inhibitors interferes with transcriptional complexes and disrupting gene transcription of key oncogenes such as MYC. Also, there is need to explore usage of other receptor tyrosine kinase inhibitors. Therefore, a drug combination strategy should be explored to overcome limited clinical efficacy. Aims: To create digital drug models for BET inhibition (BETi), CDK4/6 inhibition (CDKi), FLT3 inhibition (FLT3i) and validate the predicted responses in AML patient samples with ex vivo chemosensitivity testing. Furthermore, to validate the identified combination of BET inhibitor with CDK4/6 inhibitor or FLT3 inhibitor. Methods: The Beat AML project (supported by the Leukemia & Lymphoma Society) collects clinical data and bone marrow specimens from AML patients. Bone marrow samples are analyzed by conventional cytogenetics, whole-exome sequencing, RNAseq, and an ex vivo chemosensitivity assay. 33 patients were randomly chosen. Every available genomic abnormality was inputted into a computational biology model (CBM, Cell Works Group Inc.) that uses PubMed and other online resources to generate patient-specific protein network maps of activated and inactivated pathways. Digital drug simulations with BETi (JQ1), CDKi (palbociclib), FLT3i (sorafenib) were conducted by quantitatively measuring drug effect on a composite AML disease inhibition score (i.e., cell proliferation, viability, and apoptosis). Paired comparisons between the computational predictions and the sample's ex vivo chemosensitivity IC50 values were conducted. Results: None of the 33 AML patients showed ex vivo chemosensitivity to palbociclib alone, and the CBM method was highly accurate (94%) in predicting this lack of response (Table 1). Through CBM mapping the following genetic mutations were identified as potentially contributing to palbociclib resistance: loss of function (LOF) of RB1 (Retinoblastoma 1), LOF of PTCH1 (patched 1), LOF of FBXW7 (F-box and WD repeat domain containing 7), gain of function (GOF) of CCNE1/2 (Cyclin E1/2) or LOF in NPM1 (nucleophosmin 1). Additionally, the CBM method showed that NPM1 mutated AML cases that were resistant to palbociclib also showed a better response to the combination of palbociclib and JQ1. In 28/33 (85%) patients, this combination of palbociclib and BETi (JQ1) was toxic to AML cells in ex vivo chemosensitivity assay (Table 2). The CBM method predicted that 31/33 (94%) of AML patients would respond to palbociclib and JQ1 (Table 2), and the accuracy of matching between CBM and ex vivo chemosensitivity assay was 91% (Table 2). Another combination with high proportion of responding patients was FLT3i and BETi (Table 3), with accuracy of matching between CBM and ex vivo assay of 91% (Table 3). Furthermore, computational analysis of the combination of BETi and FLT3i revealed that patients with mutation of NPM1 along with FLT3 TKD/ITD mutation showed high degree of synergy at lower drug concentrations. Conclusion: Digital drug simulations of inhibitions of CDK4/6, BET, and FLT3 using AML patient genomic data accurately matched ex vivo chemosensitivity results. The integration of computational biology modeling and Beat AML data led to the identification of potential palbociclib resistance pathways in AML, which led to the rational design of new multi-drug regimens. This integrated system enabled novel inferences that informs future clinical trials for patients with AML.